Vorsters Alex, Arbyn Marc, Baay Marc, Bosch Xavier, de Sanjosé Silvia, Hanley Sharon, Karafillakis Emilie, Lopalco Pier Luigi, Pollock Kevin G, Yarwood Joanne, Van Damme Pierre
Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.
Unit of Cancer Epidemiology, Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium.
Papillomavirus Res. 2017 Dec;4:45-53. doi: 10.1016/j.pvr.2017.07.001. Epub 2017 Jul 20.
The Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine. However, anti-vaccination campaigns have threatened existing programs in many countries. Measurement and monitoring of HPV vaccine confidence over time could help understand the nature and scale of waning confidence, define issues and intervene appropriately using context-specific evidence-based strategies. Finally, a broad group of stakeholders, such as teachers, health care providers and the media should also be provided with accurate information and training to help support prevention efforts through enhanced understanding of the risks and benefits of vaccination. Similarly, while cervical cancer screening through population-based programs is highly effective, barriers to screening exist: awareness in countries with population-based screening programs, access for vulnerable populations, and access and affordability in low- and middle-income countries. Integration of primary and secondary prevention has the potential to accelerate the decrease in cervical cancer incidence.
人乳头瘤病毒预防与控制委员会召集专家讨论优化人乳头瘤病毒疫苗接种和筛查计划。委员会成员根据临床和上市后数据审查了已获许可的人乳头瘤病毒疫苗的安全性，达成共识认为当前的安全数据令人放心。成功的疫苗接种计划采用了协调良好的宣传活动，整合（社交）媒体以提高认知度。传播支持疫苗有效性的证据对疫苗认知产生了有益影响。然而，反疫苗运动在许多国家威胁到了现有计划。随着时间的推移对人乳头瘤病毒疫苗信心进行衡量和监测有助于了解信心下降的性质和规模，确定问题并使用因地制宜的循证策略进行适当干预。最后，还应向教师、医疗保健提供者和媒体等广泛的利益相关者提供准确信息和培训，以通过增强对疫苗接种风险和益处的理解来支持预防工作。同样，虽然通过基于人群的计划进行宫颈癌筛查非常有效，但筛查存在障碍：在实施基于人群筛查计划的国家中存在认知问题、弱势群体难以获得筛查服务，以及低收入和中等收入国家在获取筛查服务和支付能力方面存在问题。一级预防和二级预防的整合有可能加速宫颈癌发病率的下降。
